Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments.
Mahmoud S. Alghamri,Brandon L. McClellan,Margaret S. Hartlage,Santiago Haase,Syed M Faisal,Rohit Thalla,Ali Dabaja,Kaushik Banerjee,Stephen Carney,Anzar A. Mujeeb,Michael R. Olin,James J. Moon,Anna Schwendeman,Pedro R. Lowenstein,Maria G. Castro +14 more
Reads0
Chats0
TLDR
Glioblastomas are one of the most lethal types of cancers accounting for ~80% of all central nervous system (CNS) primary malignancies [1, as discussed by the authors.Abstract:
Gliomas are one of the most lethal types of cancers accounting for ~80% of all central nervous system (CNS) primary malignancies [1; 2]. Amongst gliomas, glioblastomas (GBM) are the most aggressive, characterized by a median patient survival of fewer than 15 months. Recent molecular characterization studies uncovered the genetic signatures and methylation status of gliomas and correlate these with clinical prognosis [2]. The most relevant molecular characteristics for the new glioma classification are IDH mutation, chromosome 1p/19q deletion, histone mutations, and other genetic parameters such as ATRX loss, TP53, and TERT mutations, as well as DNA methylation levels. Similar to other solid tumors, glioma progression is impacted by the complex interactions between the tumor cells and immune cells within the tumor microenvironment. The immune system’s response to cancer can impact the glioma’s survival, proliferation, and invasiveness. Salient characteristics of gliomas include enhanced vascularization, stimulation of a hypoxic tumor microenvironment, increased oxidative stress, and an immune suppressive milieu. These processes promote the neuro-inflammatory tumor microenvironment which can lead to the loss of blood-brain barrier (BBB) integrity. The consequences of a compromised BBB are deleteriously exposing the brain to potentially harmful concentrations of substances from the peripheral circulation, adversely affecting neuronal signaling, and abnormal immune cell infiltration; all of which can lead to disruption of brain homeostasis. In this review, we first describe the unique features of inflammation in CNS tumors. We then discuss the mechanisms of tumor-initiating neuro-inflammatory microenvironment and its impact on tumor invasion and progression. Finally, we also discuss potential pharmacological interventions that can be used to target neuro-inflammation in gliomas.read more
Citations
More filters
Journal ArticleDOI
RNA binding by ADAR3 inhibits adenosine-to-inosine editing and promotes expression of immune response protein MAVS
Reshma Raghava Kurup,Eimile Oakes,Aidan C. Manning,Priyanka Mukherjee,Pranathi Vadlamani,Heather A. Hundley +5 more
TL;DR: In this article , a global view of ADAR3-bound RNAs in glioblastoma cells and identifies both a role for ADAR-3 in repressing ADAR1-mediated editing and an RNA-binding dependent function of adar3 in regulating MAVS expression.
Journal ArticleDOI
Neuroinflammation and immunoregulation in glioblastoma and brain metastases: Recent developments in imaging approaches.
TL;DR: In this article, a review of recent advances in imaging methods that have helped to improve the specificity of primary tumor diagnosis versus evaluation of inflamed and necrotic brain lesions is presented.
Journal ArticleDOI
Dopamine, Immunity, and Disease
Breana Channer,Stephanie M. Matt,E. A. Nickoloff-Bybel,Vassiliki Pappa,Yash Agarwal,Jason R Wickman,Peter J. Gaskill +6 more
TL;DR: In this article , a review comprehensively assesses the current knowledge of dopaminergic immunology at the cellular, tissue, and disease level and prompts the development of therapeutics and strategies targeted toward ameliorating disease through dopamine regulation of immunity.
Journal ArticleDOI
Neuroinflammatory mediators in acquired epilepsy: an update
Yu Chen,Marwa M. Nagib,Nelufar Yasmen,Madison N. Sluter,Taylor L Littlejohn,Ying Yu,Jianxiong Jiang +6 more
Journal ArticleDOI
Metformin and Risk of Malignant Brain Tumors in Patients with Type 2 Diabetes Mellitus
TL;DR: The risk of malignant brain tumors associated with metformin use has rarely been investigated in humans as discussed by the authors, and the authors in this retrospective cohort study investigated such an association in humans.
References
More filters
Journal ArticleDOI
A dialog between glioma and microglia that promotes tumor invasiveness through the CCL2/CCR2/interleukin-6 axis.
TL;DR: A mechanism by which glioma cells exploit microglia for increased invasiveness is uncovered, and the CCL2/CCR2/IL-6 loop is a potential therapeutic target for the currently incurable malignant gliomas.
Journal ArticleDOI
Microglia/Brain Macrophages as Central Drivers of Brain Tumor Pathobiology
TL;DR: This Review discusses the complex interactions involving microglia and macrophages relevant to glioma formation, progression, and response to therapy.
Journal ArticleDOI
Microglia and macrophages in malignant gliomas: recent discoveries and implications for promising therapies.
TL;DR: Recent data that has been reported on the interaction of microglia/macrophages with brain tumors are summarized and potential application of these findings to the development of future antiglioma therapies are discussed.
Journal ArticleDOI
A vaccine targeting mutant IDH1 in newly diagnosed glioma.
Michael Platten,Michael Platten,Lukas Bunse,Lukas Bunse,Antje Wick,Theresa Bunse,Theresa Bunse,Lucian Le Cornet,Inga Harting,Felix Sahm,Khwab Sanghvi,Chin Leng Tan,Isabel Poschke,Edward W. Green,Sune Justesen,Geoffrey A. Behrens,Michael O. Breckwoldt,Angelika Freitag,Lisa-Marie Rother,Anita Schmitt,Oliver Schnell,Jörg Hense,Martin Misch,Dietmar Krex,Stefan Stevanovic,Ghazaleh Tabatabai,Joachim P. Steinbach,Martin Bendszus,Andreas von Deimling,Michael Schmitt,Wolfgang Wick +30 more
TL;DR: In this paper, an IDH1(R132H)-specific peptide vaccine (IDH1-vac) was used to induce specific therapeutic T helper cell responses that are effective against the most common IDH 1 mutation in diffuse gliomas, which harbours a shared clonal neoepitope.
Journal ArticleDOI
Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis
Nathan Mathewson,Orr Ashenberg,Itay Tirosh,Simon Gritsch,Simon Gritsch,Elizabeth M. Perez,Sascha Marx,Livnat Jerby-Arnon,Rony Chanoch-Myers,Toshiro Hara,Toshiro Hara,Alyssa R. Richman,Alyssa R. Richman,Yoshinaga Ito,Jason Pyrdol,Mirco Friedrich,Kathrin Schumann,Kathrin Schumann,Michael J. Poitras,Prafulla C. Gokhale,L. Nicolas Gonzalez Castro,Marni E. Shore,Marni E. Shore,Christine M. Hebert,Christine M. Hebert,Brian A. Shaw,Heather L. Cahill,Matthew Drummond,Wubing Zhang,Olamide Olawoyin,Hiroaki Wakimoto,Orit Rozenblatt-Rosen,Orit Rozenblatt-Rosen,Priscilla K. Brastianos,X. Shirley Liu,Pamela S. Jones,Daniel P. Cahill,Matthew P. Frosch,David N. Louis,Gordon J. Freeman,Keith L. Ligon,Alexander Marson,Alexander Marson,E. Antonio Chiocca,David A. Reardon,David A. Reardon,Aviv Regev,Mario L. Suvà,Mario L. Suvà,Kai W. Wucherpfennig +49 more
TL;DR: In this paper, single-cell RNA sequencing (RNA-seq) was used to chart the gene expression and clonal landscape of tumor-infiltrating T cells across 31 patients with isocitrate dehydrogenase (IDH) wild-type glioblastoma and IDH mutant glioma.